# US 11,897,953 B2 · Compositions and methods targeting complement component 3 for inhibiting tumor growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,897,953 B2
- Document ID: US11897953B2
- Status: Granted
- Kind: B2
- Application number: 16/622,636
- Filed: 2018-06-14
- Published: 2020-04-02
- Granted: 2024-02-13
- Earliest claimed: 2017-06-14
- Assignees: The Broad Institute, Inc.; Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc.
- Applicants: The Broad Institute, Inc.; Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc.
- Inventors: Aviv Regev; Ana Carrizosa Anderson; Ayshwarya Subramanian; Orit Rozenblatt-Rosen
- Web page: https://patentgrep.com/patent/US11897953B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 40/10: characterised by the cell type used
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 5/0636: {T lymphocytes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2239/50: Colon
- A61K 2239/57: Skin; melanoma
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 2501/599: with CD designations not provided for elsewhere
- C12Q 2600/158: Expression markers
- G16B 30/10: Sequence alignment; Homology search
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.

## Claims

### Claim 1

An isolated CD8+ T cell genetically modified to decrease the expression of complement receptor CR1 (CD35) and/or CR2 (CD21) wherein the T cell is a tumor infiltrating lymphocyte (TIL) and/or expresses an endogenous T cell receptor (TCR) or a chimeric antigen receptor (CAR), wherein said TCR or CAR targets a tumor-specific or tumor-associated antigen.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising one or more cells according to claim 1.

### Claim 3 (depends on 2)

A method of treating cancer in a subject in need thereof, comprising administering the pharmaceutical composition of claim 2 to the subject.